indazoles has been researched along with Epithelial Ovarian Cancer in 57 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 25 (43.86) | 24.3611 |
| 2020's | 32 (56.14) | 2.80 |
| Authors | Studies |
|---|---|
| Baek, SH; Kim, BG; Lim, MC; Noh, JJ; Park, SY; Shin, W | 1 |
| Lee, A | 1 |
| Choi, MC; Jeong, DH; Kim, BG; Kim, SI; Lee, JK; Lee, JY; Lim, MC; Park, J | 1 |
| Alexandre, J; Kalbacher, E; Leary, A; Prulhière, K; Ray-Coquard, I; Selle, F | 1 |
| Agouridis, AP; Mamais, I; Michalinos, A; Pagkali, A | 1 |
| Artioli, G; Baumann, K; Bradley, WH; Calvert, PM; Dørum, A; Forget, F; Fuentes, J; González-Martín, A; Gupta, D; Hietanen, S; Kumar, A; Levy, T; Li, Y; Malinowska, IA; McCormick, C; Monk, BJ; Moore, RG; O'Cearbhaill, RE; O'Malley, DM; Pérez-Fidalgo, JA; Selle, F; Shahin, MS; Slomovitz, BM; Tusquets, I; Vulsteke, C | 1 |
| Cancanelli, L; Chiumente, M; Di Spazio, L; Mengato, D; Messori, A; Rivano, M | 1 |
| Feng, Y; Jia, H; Jiang, R; Jiang, W; Liu, J; Shi, T; Teng, Y; Wang, H; Wang, X; Wu, S; Xiang, L; Yu, A; Zang, R; Zhang, J; Zhang, P; Zhang, W; Zhang, Y; Zhu, J; Zhu, T; Zhu, Y | 1 |
| González-Martín, A; Gupta, D; Korach, J; Lechpammer, S; Matulonis, UA; Mirza, MR; Monk, BJ; Moore, KN; Wu, X; York, W | 1 |
| Barquin, A; Churruca, C; Constenla, M; Cueva, JF; de Juan, A; Estévez, P; Fernández, I; Gallego, A; García, Y; González-Martín, A; Guerra, E; Herrero, A; Juárez, A; Legerén, M; Manso, L; Marquina, G; Martín, C; Martín, T; Martínez Bueno, A; Maximiano, C; Palacio, I; Pardo, B; Quindós, M; Sánchez, L; Santaballa, A; Yubero, A | 1 |
| Buckley, L; González-Martin, A; Matulonis, UA; Mirza, MR; Monk, BJ; Moore, KN; Rimel, BJ; Wu, X | 1 |
| Baumann, K; Baurain, JF; Calvert, PM; Denys, H; Follana, P; Gaba, L; Ghamande, SA; González-Martín, A; Graybill, WS; Guerra, EM; Gupta, D; Korach, J; Li, Y; Malinowska, IA; Mirza, MR; Monk, BJ; O'Malley, DM; Pisano, C; Prendergast, E; Rose, PG; Stephanie Yap, OW | 1 |
| Ikeda, Y; Kajiyama, H; Nei, T; Niimi, K; Tamauchi, S; Yoshikawa, N | 1 |
| Backes, F; Compton, N; Freyer, G; González-Martín, A; Graybill, W; Heitz, F; Lorusso, D; Malinowska, IA; McCormick, CC; Mirza, MR; Monk, BJ; Moore, RG; O'Cearbhaill, RE; Pothuri, B; Redondo, A; Shtessel, L; Vergote, I; Vulsteke, C | 1 |
| Cai, H; Cui, H; Hang, W; Hao, M; Hou, J; Huang, Y; Kong, B; Li, G; Li, N; Lin, A; Liu, J; Liu, Z; Lou, G; Lu, W; Pan, L; Pan, Y; Qu, P; Wang, C; Wang, J; Wang, K; Wang, L; Wu, L; Wu, X; Yang, H; Yang, Y; Yao, S; Yin, R; Zhang, Y; Zhao, H; Zhen, X; Zheng, H; Zhu, J; Zou, D | 1 |
| Ngan, RKC | 1 |
| Chen, B; Chen, J; He, A; Hou, W; Jia, M; Jiang, Z; Li, M; Miao, P; Qiu, S; Shao, Z; Shen, Y; Sun, W; Wu, X; Xu, J; Xu, X; Yuan, D; Zhang, B; Zhang, Y; Zhao, M; Zhou, Y; Zhu, T; Zhu, Y | 1 |
| Adams, S; Baines, A; Chon, HS; Cloven, NG; Coleman, RL; Dalton, H; Duska, LR; ElNaggar, AC; Gaillard, S; Holloway, RW; Huang, M; Konstantinopoulos, PA; Monk, BJ; Nelsen, LM; O'Cearbhaill, RE; O'Malley, DM; Randall, LM; Samnotra, V; Striha, A; Tarkar, A; Waggoner, S | 1 |
| Bologna, A; Calvert, PM; Carrasco-Alfonso, MJ; Colombo, N; Del Campo, JM; du Bois, A; Floquet, A; Friedlander, M; Fujiwara, K; Hanker, LC; Harter, P; Herzog, TJ; Kim, JW; Lee, JY; Meunier, J; Mirza, MR; Monk, BJ; Pignata, S; Rau, J; Tsibulak, I; Vergote, I | 1 |
| Cui, M; Han, L; Wang, L; Wang, Q; Xu, Y | 1 |
| Walsh, CS | 1 |
| Banerjee, S; Clamp, AR; Dive, C; Hall, M; Hasan, J; Jayson, GC; Lyon, AR; Morgan, RD; Orbegoso, C; Rustin, GJS; Taylor, S; Tugwood, J; Zhou, C | 1 |
| Bhatla, N; Khurana, S; Kumar, L; Kumar, S; Malik, PS; Ray, MD; Sharma, A | 1 |
| Bhatti, A; Horton, ER; Kerliu, L; Myruski, S; Pervanas, HC; Petrosius, P; Soni, P | 1 |
| Bai, J; Kristeleit, R; Monk, BJ; Moore, KN; Tewari, KS; Wolford, JE | 1 |
| Bajpai, J; Deodhar, K; Ghosh, J; Gulia, S; Gupta, S; Maheshwari, A; Rath, S; Shylasree, TS; Thakur, M | 1 |
| Barroilhet, LM; Brown, J; Darus, C; Duska, LR; Jelovac, D; McGuire, WP; Moore, KN; Petroni, GR; Secord, AA; Varhegyi, N | 1 |
| Barrington, DA; Cohn, DE; Senter, L; Smith, HJ; Straughn, JM; Tubbs, C | 1 |
| Barceló, IB; Benigno, B; Berton-Rigaud, D; Bessette, P; Buscema, J; de Jong, FA; du Bois, A; Dørum, A; Gupta, D; Herráez, AC; Herrstedt, J; Kalbacher, E; Lau, S; Ledermann, JA; Levy, T; Lorusso, D; Mahner, S; Matulonis, UA; Mirza, MR; Rimel, BJ; Vergote, I; Wang, P | 1 |
| Penn, CA; Walsh, CS; Wong, MS | 1 |
| Alvarez, N; Colombo, N; dePont Christensen, R; Gonzalez Martin, A; Heitz, F; Marqués, C; Meirovitz, M; Sanchez Lorenzo, L; Sanchez, J; Selle, F; van Gorp, T | 1 |
| Hong, SH | 1 |
| Liu, MC; Sutedja, J; Tewari, KS | 1 |
| Chauhan, R; Khurana, S; Kumar, L; Kumar, S; Malik, PS; Mathur, S; Sharma, A; Singh, M; Sreenivas, V | 1 |
| Scott, LJ | 1 |
| Dinkic, C; Eichbaum, M; Fricke, HC; Gebauer, G; Grischke, EM; Lenz, F; Marme, F; Rom, J; Schmidt, M; Schneeweiss, A; Sohn, C; Wallwiener, M | 1 |
| Aghajanian, C; Alvarez Secord, A; Carney, ME; Coleman, RL; Gray, HJ; Hanjani, P; Hu, W; Kehoe, SM; Landrum, LM; Lankes, HA; Pearl, ML; Richardson, DL; Sill, MW; Sood, AK; Van Le, L; Zhou, XC | 1 |
| Barrett, C; Bologna, A; Buck, M; Calvert, P; Debruyne, P; du Bois, A; Friedlander, M; Herzog, TJ; Hilpert, F; Kim, JW; King, MT; Lee, CK; Lesoin, A; Malander, S; Meier, W; Monk, BJ; Petru, E; Poveda, A; Rau, J; Scambia, G; Shimada, M | 1 |
| Matulonis, UA; Mirza, MR; Moore, KN | 1 |
| Longoria, TC; Tewari, KS | 1 |
| Ethier, JL; Lheureux, S; Oza, AM | 1 |
| Agarwal, S; Banerjee, S; Benigno, B; Berek, JS; Berton-Rigaud, D; Buscema, J; D'Hondt, V; Del Campo, JM; Hilpert, F; Hudgens, S; Lund, B; Malander, S; Matulonis, UA; Mirza, MR; Oza, AM; Provencher, D; Scambia, G; Sehouli, J; Tinker, AV; Vázquez, IP | 1 |
| Coleman, RL; Kurnit, KC; Westin, SN | 1 |
| Gao, H; Guo, X; Li, X; Liu, N; Peng, S; Wang, K; Wu, W; Yu, J; Zhan, G; Zhu, Y | 1 |
| Callahan, T; Chan, JK; Guo, W; Moore, K; Patel, MR; Secord, AA; Zhang, ZY | 1 |
| Azodi, M; Berek, JS; Chan, JK; Cloven, N; Cristea, M; DiSilvestro, P; Fleming, GF; Geller, MA; Li, Y; Luptakova, K; Matei, DE; Matulonis, UA; Miller, DS; Monk, BJ; Moore, KN; Oza, AM; Rimel, BJ; Secord, AA; Sun, K; Wahner Hendrickson, AE | 1 |
| Fagotti, A; Marchetti, C; Scambia, G | 1 |
| Åvall-Lundqvist, E; Bergmann, TK; Birrer, MJ; Bjørge, L; Brøsen, K; Christensen, RD; Jørgensen, M; Lassen, U; Mäenpää, J; Malander, S; Mau-Sørensen, M; Mirza, MR; Nielsen, F; Roed, H | 1 |
| Amatangelo, MD; Conejo-Garcia, JR; Garipov, A; Li, H; Speicher, DW; Zhang, R | 1 |
| Klempner, SJ; Mills, GB; Myers, AP; Westin, SN | 1 |
| Barrett, C; Calvert, P; Colombo, N; Crescenzo, RJ; del Campo, JM; du Bois, A; Fiane, B; Floquet, A; Friedlander, M; Herzog, TJ; Isonishi, S; Kim, JW; Meier, W; Mitrica, I; Monk, BJ; Pisano, C; Reinthaller, A; Vergote, I; Wang, K | 1 |
| Chua, CC; Earwood, CB; Firdaus, ID; Hainsworth, JD | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Cox, CJ; Crescenzo, R; du Bois, A; Harter, P; Kim, BG; Kim, JW; Kong, BH; Liu, JH; Mahner, S; Mitrica, I; Ngan, HY; Park, SY; Shoji, T; Takano, T; Wang, KL; Wang, Q; Wei, LH; Wu, LY; Wu, Q; Zhang, P; Zhu, JQ | 1 |
| Barrett, C; Berton-Rigaud, D; Chan, JK; Colombo, N; Del Campo, JM; du Bois, A; Forget, F; Friedlander, M; Harter, P; Heitz, F; Herzog, TJ; Imhof, M; Jobanputra, M; Johnson, T; King, K; Mirza, MR; O'Donnell, D; Park, SY; Shimada, M; Stinnett, S; Xu, CF; Zamagni, C | 1 |
| Bischofs, E; Eichbaum, M; Eickhoff, R; Fehm, T; Fersis, N; Fricke, HC; Gebauer, G; Lenz, F; Mayer, C; Schmidt, M; Schneeweiss, A; Sohn, C; Solomayer, E; Wallwiener, M | 1 |
| Kim, W; Kim, YJ; Kwak, SW; Lee, CS; Lee, JJ; Lee, MS; Lee, SA; Myung, SC; Park, ES | 1 |
15 review(s) available for indazoles and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer.
Topics: Adult; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Maintenance Chemotherapy; Ovarian Neoplasms; Piperidines | 2021 |
Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Maintenance Chemotherapy; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2021 |
Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines | 2022 |
Niraparib treatment for patients with
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life | 2022 |
Safety and management of niraparib monotherapy in ovarian cancer clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life | 2023 |
First-line maintenance therapy with niraparib in advanced platinum-sensitive ovarian cancer: two 'long responder' case reports and review of the current literature.
Topics: Asian People; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2023 |
Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Topics: Antineoplastic Agents; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; DNA Repair; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2020 |
Latest clinical evidence of maintenance therapy in ovarian cancer.
Topics: Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic | 2020 |
Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Topics: Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival | 2020 |
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
Topics: Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Female; Humans; Indazoles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2018 |
Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life | 2018 |
The role of niraparib for the treatment of ovarian cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Mutation; Neoplasm Recurrence, Local; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2018 |
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carbazoles; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Phthalazines; Phthalimides; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2018 |
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
24 trial(s) available for indazoles and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Republic of Korea | 2022 |
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
Topics: Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Piperidines | 2022 |
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Topics: Body Weight; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prospective Studies | 2023 |
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Maintenance Chemotherapy; Ovarian Neoplasms; Progression-Free Survival | 2023 |
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Progression-Free Survival | 2023 |
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life | 2023 |
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Pyrimidines; Quality of Life; Sulfonamides; Treatment Outcome; Young Adult | 2019 |
Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cardiotoxicity; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Ovarian Neoplasms; Progression-Free Survival; Pyrimidines; Stilbenes; Sulfonamides; Survival Rate | 2020 |
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Indazoles; Middle Aged; Peritoneal Neoplasms; Pyrimidines; Sulfonamides | 2020 |
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Topics: Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival | 2020 |
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Peritoneal Neoplasms; Piperidines; Platinum; Progression-Free Survival; Time Factors | 2021 |
Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Progression-Free Survival; Pyrimidines; Quality of Life; Sulfonamides | 2021 |
Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Indazoles; Leukopenia; Liver Function Tests; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds; Pyrimidines; Sulfonamides | 2017 |
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Placebos; Progression-Free Survival; Proto-Oncogene Mas; Pyrimidines; Sulfonamides; Treatment Outcome | 2018 |
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance th
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Patient Reported Outcome Measures; Progression-Free Survival; Pyrimidines; Quality of Life; Sulfonamides; Time-to-Treatment | 2018 |
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Patient Reported Outcome Measures; Piperidines; Progression-Free Survival; Quality of Life; Surveys and Questionnaires | 2018 |
Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Topics: Aged; Carcinoma, Ovarian Epithelial; Cardiotoxicity; Double-Blind Method; Electrocardiography; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Long QT Syndrome; Middle Aged; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2019 |
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Topics: Adolescent; Adult; Aged; BRCA1 Protein; BRCA2 Protein; Canada; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Middle Aged; Mutation; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Time Factors; United States; Young Adult | 2019 |
A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival | 2019 |
Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.
Topics: Angiogenesis Inhibitors; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Double-Blind Method; Endpoint Determination; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrimidines; Sulfonamides | 2015 |
Pazopanib and liposomal doxorubicin in the treatment of patients with relapsed/refractory epithelial ovarian cancer: a phase Ib study of the Sarah Cannon Research Institute.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Indazoles; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Pyrimidines; Sulfonamides | 2015 |
Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study.
Topics: Adult; Aged; Aged, 80 and over; Asia, Eastern; Asian People; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Double-Blind Method; Female; Humans; Indazoles; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Vascular Endothelial Growth Factor Receptor-1; Young Adult | 2018 |
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Genome-Wide Association Study; Germ-Line Mutation; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrimidines; Sulfonamides; White People; Young Adult | 2016 |
The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Pyrimidines; Sulfonamides | 2011 |
18 other study(ies) available for indazoles and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Real-world Experience of Niraparib in Newly-diagnosed Epithelial Ovarian Cancer.
Topics: Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Drug Tapering; Feasibility Studies; Female; Humans; Indazoles; Maintenance Chemotherapy; Neoplasm Staging; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Republic of Korea; Retrospective Studies; Survival Analysis; Treatment Outcome | 2021 |
Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.
Topics: Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2022 |
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors | 2023 |
Niraparib as a therapeutic agent for the treatment of ovarian cancer meningeal dissemination with BRCA1 mutation.
Topics: BRCA1 Protein; Carcinoma, Ovarian Epithelial; Female; Germ-Line Mutation; Humans; Indazoles; Middle Aged; Mutation; Ovarian Neoplasms | 2023 |
Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China.
Topics: Aged; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2023 |
Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis.
Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Celecoxib; Cyclophosphamide; Drug Therapy; Etoposide; Female; Humans; Indazoles; India; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Pyrimidines; Recurrence; Sulfonamides | 2019 |
Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Cost-Benefit Analysis; Drug Costs; Female; Humans; Indazoles; Indoles; Infusions, Intravenous; Markov Chains; Models, Statistical; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life; United States | 2020 |
Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Pyrimidines; Retrospective Studies; Sulfonamides | 2020 |
Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis.
Topics: Carcinoma, Ovarian Epithelial; Cost-Benefit Analysis; Decision Support Techniques; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Quality-Adjusted Life Years | 2020 |
Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
Topics: Antineoplastic Agents, Immunological; Bevacizumab; Carcinoma, Ovarian Epithelial; Computing Methodologies; Cost-Benefit Analysis; Female; Genes, BRCA1; Genes, BRCA2; Homologous Recombination; Humans; Indazoles; Maintenance Chemotherapy; Medicare; Neoplasm Staging; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; United States | 2020 |
How to start niraparib in real-world Asian ovarian cancer patients?
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2021 |
Niraparib in the maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: safety and efficacy.
Topics: Carcinoma, Ovarian Epithelial; Fallopian Tubes; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2021 |
Niraparib: First Global Approval.
Topics: Adult; Carcinoma, Ovarian Epithelial; Double-Blind Method; Drug Approval; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2017 |
β-hCG promotes epithelial ovarian cancer metastasis through ERK/MMP2 signaling pathway.
Topics: Animals; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chorionic Gonadotropin, beta Subunit, Human; Female; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Indazoles; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Piperazines; Receptors, LH | 2019 |
Fighting against the challenge of treating patients with late-line ovarian cancer: are we there yet?
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2019 |
Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Enhancer of Zeste Homolog 2 Protein; Female; Humans; Indazoles; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polycomb Repressive Complex 2; Pyridones; Tumor Microenvironment | 2013 |
Guanylate cyclase activator YC-1 potentiates apoptotic effect of licochalcone A on human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathways.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma; Carcinoma, Ovarian Epithelial; Caspases; Cell Line, Tumor; Cell Nucleus; Chalcones; Drug Interactions; Enzyme Activation; Female; Guanylate Cyclase; Humans; Indazoles; Neoplasm Proteins; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteolysis; Signal Transduction; Tumor Suppressor Protein p53 | 2012 |